Phase I clinical and pharmacokinetic trial of vinflunine (10070) a novel fluorinated vinca alkaloid in patients (pts) with advanced solid malignancies: Preliminary results.

被引：0
|
作者：
Fumoleau, P
Bennouna, J
Raymond, E
Armand, JP
Hocini, A
Blanchot, G
Delgado, FM
Marty, M
机构：
[1] Rene Gauducheau Canc Ctr, Nantes, France
[2] Inst Gustave Roussy, Villejuif, France
[3] St Louis Hosp, Paris, France
[4] Pierre Fabre Res Inst, Boulogne, France
来源：
CLINICAL CANCER RESEARCH | 2000年 / 6卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
576
引用
收藏
页码：4581S / 4581S
页数：1
相关论文
共 50 条
  • [1] Phase I clinical and pharmacokinetic trial of vinflunine: A novel fluorinated vinca alkaloid given on day 1 every 21 days.
    Fumoleau, P
    Bennouna, J
    Armand, JP
    Blanchot, G
    Delgado, FM
    Marty, M
    BRITISH JOURNAL OF CANCER, 2001, 85 : 94 - 94
  • [2] Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
    Fiedler, W. M.
    Giaccone, G.
    Lasch, P.
    Van der Horst, I.
    Brega, N. M.
    Raber, S.
    Shalinsky, D.
    Ljubmir, V.
    Bokemeyer, C.
    Boven, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies
    Esteve, F. R.
    Stoller, R. G.
    Josephson, A.
    Grandis, J. R.
    Egorin, M. J.
    Argiris, A. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF AVE8062, A NOVEL VASCULAR DISRUPTING AGENT, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS - PRELIMINARY RESULTS
    Sessa, C.
    Soria, J. C.
    Tolcher, A.
    LoRusso, P.
    Cohen, P.
    ANNALS OF ONCOLOGY, 2009, 20 : 24 - 24
  • [5] Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies
    Feinstein, T. M.
    Agrawal, S.
    Stoller, R. G.
    Egorin, M. J.
    Argiris, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial
    Hahn, L.
    Irenaeus, S.
    Wenthe, J.
    Eriksson, E.
    Schiza, A.
    Dahlstrand, H.
    Olsson-Stromberg, U.
    Krause, J.
    Sundin, A.
    Sandin, L. C.
    Jarblad, J. Leja
    Liljefors, M.
    Loskog, A.
    Ullenhag, G. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S674 - S674
  • [7] A phase I clinical and pharmacokinetic study of ipifarnib in combination with docetaxel in patients with advanced solid malignancies
    Awada, Ahmad
    Zhang, Steven
    Gil, Thierry
    de Valeriola, Dominique
    Lalami, Yassine
    De Porre, Peter
    Piccart-Gebhart, Martine J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 991 - 1003
  • [8] INFLUENCE OF AGE ON THE PHARMACOKINETIC OF IV VINFLUNINE: RESULTS OF A PHASE I TRIAL IN ELDERLY CANCER PATIENTS
    Tourani, J.
    Isambert, N.
    Mourey, L.
    Girre, V.
    Servent, V.
    Ravaud, A.
    Favrel, S.
    Pinel, M.
    Pivot, X.
    ANNALS OF ONCOLOGY, 2010, 21 : 186 - 186
  • [9] Phase I and pharmacokinetic study of vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results.
    Tourani, JM
    Pinel, MC
    Planchard, D
    Aslanis, V
    Gouva, S
    Robinet, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 688S - 688S
  • [10] Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies.
    Dupont, J
    Schwartz, L
    Koutcher, J
    Spriggs, D
    Gordon, M
    Mendelson, D
    Murren, J
    Lucarelli, A
    Cedarbaum, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 197S - 197S
12345